Vinorelbine

• Radiation-Sensitizing Agents
• Antineoplastic Agents
• ATC:L01CA04

• Navelbine
• Navelbine Base
• Vinorelbin
• Vinorelbina [Spanish]
• Vinorelbine Bitartrate
• Vinorelbine Ditartarate
• Vinorelbine Ditartrate
• Vinorelbine Tartrate
• Vinorelbinum [Latin]

• No information avaliable

C₄₅H₅₄N₄O₈

http://www.rxlist.com/cgi/generic2/vinor.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=136

No information avaliable

778.932 g/mol

No information avaliable

No information avaliable

Solid

5.829

Solution

For the treatment of non-small-cell lung carcinoma

Vinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

No information avaliable

No information avaliable

No information avaliable

Humans and other mammals